Cognis sets up Indian subsidiary
This article was originally published in Scrip
Executive Summary
Cognis has set up a wholly-owned subsidiary, Cognis Specialty Chemicals, in Mumbai. Cognis, which first opened a liaison office in India in February last year, expects the new affiliate to continue to grow its business in the country. Last year Cognis' sales in India grew by about 30%. The company supplies innovative ingredients for products such as pharmaceuticals, personal and home care, food ingredients and dietary supplements and has been increasingly allocating resources to its operations in the Asia-Pacific region. This is now its third-biggest market after Europe and North America. Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences.
You may also be interested in...
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.